Geron
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
919 E Hillsdale Blvd Ste 250, Foster Cit...Phone Number
(650) 473-7700Website
www.geron.comRevenue
$196.1 MillionStock Symbol
GERNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.Explore more
Geron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Geron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Geron recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Geron has new funding data
Check if Geron has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Geron
Check out if Geron is spiking on competitors!
Product Launch: Get notified when Geron launches new products
Geron, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Geron had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Geron
Compare insights from companies similar to Geron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Geron is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Geron is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Geron.
Geron financials insights
Gather financial insights about Geron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1996
Stock Offering
$16M
2020
Debt
$75M
2024
Debt
$375M
Geron Tech Stack
A closer look at the technologies used by Geron
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Geron has completed enrollment in its Phase III in myelofibrosis patients who are relapsed or refractory to ruxolitinib, with an interim analysis based on the primary endpoint of overall survival expected before the end of the current year, and full data maturity projected for the second half of 2028.
Clinical Operations
Project
Geron has restructured its internal performance tracking framework to incorporate early indicators such as demand growth, new account acquisition (growing by 100 to 150 new accounts per quarter), and patient source mix, while also realigning its internal incentive system to reward second-line RYTELO prescribing performance.
CRM, Sales, Business Development, Account Management
Executive Move
Executive Moves, Board of Directors
Person-Based
Pharmaceuticals, Clinical Operations
Geron News & Media
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call andGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron’s new Chief Business Officer, as an inducement material to his acceptance of employment with Geron.Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companiesGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Geron
Sign Up For FreeTo access detailed company insights
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosi... Read More
